Latest revenue
—
as of 2025-12-31
Latest net income
$-36.2M
as of 2025-12-31
Net margin
—
as of 2025-12-31
Community sentiment
Where do you think PHGE is heading?
Keep private notes on PHGE — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
PHGE vs S&P 500 · rebased to 100
Live market
delayed ≤15 min- Market cap
- $6.8M
- Enterprise value
- $18.1M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $8.50
- 52-wk low
- $0.24
- Beta
- —
- Shares out
- 10.1M
What this company does
ITEM 1. BUSINESS Overview We are a clinical stage product discovery company developing products using both natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases, such as diabetic foot infections, or DFI. Bacteriophage or phage are bacterial, species-specific, strain-limited viruses that infect, amplify and kill the target bacteria and are considered inert to mammalian cells. By utilizing proprietary combinations of naturally occurring phage and by creating novel phage using synthetic biology, we develop phage-based therapies intended to address large-market diseases. Based on the urgency of treating the infection…
AI summary unavailable — showing raw filing excerpt
Generated from PHGE's filing dated 2026-02-19
Key risks
ITEM 1A. RISK FACTORS You should carefully consider the risks and uncertainties described below and the other information in this Annual Report before making an investment in our securities. Our business, financial condition, results of operations, or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our securities could decline and you could lose all or part of your investment. This Annual Report also contains forward-looking statements that involve risks and uncertainties. See “Cautionary Statement Regarding Forward-Looking Statements.” Our actual results could differ materially and adversely from those anticipated in…
AI summary unavailable — showing raw filing excerpt
Generated from PHGE's filing dated 2026-02-19
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 10, 2026.